Life Sciences Neurology Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Neurology Therapeutics
1.1 - About Life Sciences Neurology Therapeutics sector
Companies in Life Sciences Neurology Therapeutics discover, develop, manufacture, and support therapies and technologies targeting epilepsy, sleep disorders, pain, addiction, and other CNS conditions. They provide approved prescription medicines, investigational gene therapies, neuromodulation devices, and clinical support services that improve patient outcomes, reduce opioid reliance, and accelerate time‑to‑market through integrated CDMO and analytical capabilities, medical affairs resources, and business development partnerships.
Offerings typically span anti-seizure medications and sleep disorder therapies formulated for chronic CNS management. Companies also deliver opioid-sparing analgesics for acute and severe pain, addiction treatment drugs, and investigational AAV gene therapy candidates for durable disease modification. Many complement therapeutics with Transcranial Magnetic Stimulation platforms and home electrotherapy devices (TENS, IFC, NMES), alongside contract development and manufacturing, GMP analytical testing, and medical affairs portals that disseminate evidence and prescribing guidance.
Primary customers include hospitals and health systems, neurology and psychiatry clinics, and biopharma partners pursuing licensing or CDMO support. Buyers achieve faster regulatory readiness and market access, improved clinical outcomes with reduced opioid exposure, stronger formulary adoption via robust evidence, and expanded pipelines through co-development and asset acquisition. These strategic buyers in neurology favor scalable platforms, reliable manufacturing, and comprehensive medical information for safe, consistent use.
2. Buyers in the Life Sciences Neurology Therapeutics sector
2.1 Top strategic acquirers of Life Sciences Neurology Therapeutics companies
Lundbeck
- Description: Provider of pharmaceutical contract development and manufacturing services specializing in solid-dosage drug products, offering end-to-end development, clinical and commercial batch production, analytical, packaging and supply-chain support from ISO-certified sites in Denmark and France.
- Key Products:
- Contract Development & Manufacturing (CDM): Provides formulation development, clinical and commercial solid-dosage production plus integrated packaging using advanced facilities in Denmark and France, enabling rapid time-to-market
- Analytical Services: Operates fully equipped laboratories delivering comprehensive testing and regulatory-compliant analytical support throughout product lifecycle to ensure quality and safety
- Supply Chain Services: Manages storage and global shipping, including controlled narcotic and psychotropic products, ensuring continuous availability and full regulatory compliance for customers
- Quality & HSE Management: Implements ISO 14001 and ISO 45001 certified quality, safety and environmental systems that safeguard high manufacturing standards and operational excellence across all activities.
- Rationale: Provider of CDM solid-dosage production, Analytical Services regulatory testing, and Supply Chain Services controlled narcotic shipping for CNS.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Neurology Therapeutics sector
M&A buyer group 1: Pain Management
Ethypharm
- Type: N/A
- Employees: ●●●●●
- Description: Provider of essential medicines with strong European roots, manufacturing hospital injectables and complex oral solid forms for central nervous system disorders such as severe pain and addiction, plus treatments for critical care and internal medicine. Operates six production sites in France, the UK, Spain and China and markets its portfolio in 68 countries through direct presence and strategic partners.
- Key Products:
- Severe Pain Treatment Medicines: Pharmaceutical formulations developed to alleviate severe pain, produced for hospital use and central nervous system indications, ensuring reliable analgesic effect
- Addiction Treatment Medications: Pharmaceutical products designed to address addiction disorders, enabling healthcare professionals to mitigate dependence and improve long-term patient outcomes
- Critical Care Medications: Hospital-grade drugs manufactured for urgent life-saving interventions in intensive care, supporting clinicians during cardiovascular emergencies and other acute conditions
- Aurum Range Pre-filled Syringes: Sterile emergency drug syringes featuring new 10ml CONNECT barrel with wider internal channel and fixed Luer lock, expanding needle-free connector compatibility.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Neurology Therapeutics sector
3.1 - Buyout funds in the Life Sciences Neurology Therapeutics sector
2.2 - Strategic buyer groups for Life Sciences Neurology Therapeutics sector
4 - Top valuation comps for Life Sciences Neurology Therapeutics companies
4.2 - Public trading comparable groups for Life Sciences Neurology Therapeutics sector
Valuation benchmark group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.